CAMBRIDGE, England & EDINBURGH, Scotland–(BUSINESS WIRE)–Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media and characterization services for life science discovery, today announced that its human induced pluripotent stem cell-derived ventricular cardiomyocytes ( iPSC) have been extensively studied in vitro validation of the pro-arrhythmia test (CiPA). Using this assay, the cells have been shown to be suitable for measuring cardiotoxicity, providing scientists with a robust cardiac model for drug discovery and screening.
Axol’s human iPSC-derived ventricular cardiomyocytes are manufactured at scale under strict quality control standards using ISO 9001 accredited quality management systems, providing a continuous source of cells of the same genetic heritage to use in multiple experiments. This offers physiological relevance in vitro research model of human heart cells to reliably and repeatedly test drug candidates for large-scale cardiotoxicity.
With the advent of iPSC-derived human cardiomyocytes, the US Federal Food and Drug Administration (FDA) has launched a task force to assess the usefulness of these cells in reproducing cardiotoxicity in a box, known as CiPA*. The test tests cells with 28 compounds known to be cardiotoxic and induce the deadly “Torsades de Pointes” arrhythmia. Clyde Biosciences, a CRO specializing in cardiotoxicity testing, used this assay to validate Axol’s cardiomyocytes for cardiac safety testing. Using these cells could help researchers identify unsuitable drug candidates earlier in the drug discovery process and increase the number of promising preclinical drug candidates that translate to clinical trials and for patients.
Liam Taylor, CEO of Axol Bioscience, said: “Scientists need cells and reagents they can rely on to perform meaningful toxicity assessments of drug candidates, before advancing candidates to the clinic.
We are both excited and proud to demonstrate the suitability of our iPSC-derived human ventricular cardiomyocytes for toxicity testing. Axol’s strict quality control standards mean we have the ability to produce reliable, validated cells that scientists can use to assess a compound’s cardiac liability and ultimately help improve the discovery process. of drugs.
Professor Godfrey Smith, CSO, Clyde Biosciences, added: “As a core member of the CiPA initiative, we are delighted to have supported Axol’s cell development and helped the team assess the performance of their cardiomyocytes. After running the CiPA protocol on Clyde’s proprietary CellOPTIQ platform and providing data analysis and interpretation, we confirm that our data indicate that Axol cardiomyocytes meet the prediction requirements. in vitro pro-arrhythmia screening.”
For more information on Axol’s human iPSC-derived cardiomyocytes, please visit: https://axolbio.com/cells/cardiovascular-system/
Dr. Jamie Bhagwan, Group Leader, Axol Bioscience will present data describing the development of Axol’s iPSC-derived cardiomyocytes alongside Professor Godfrey Smith of Clyde Biosciences in a free webinar on June 9e, at 6 p.m. BST / 1 p.m. ET / 10 a.m. PT. Register here: https://register.gotowebinar.com/register/1085358037527496720?hss_channel=lcp-
Axol will also be attending the International Society for Stem Cell Research (ISSCR) Annual Meeting in San Francisco, USA, June 15-18, 2022. Visit Booth 440 to learn more.
* About CiPA: https://cipaproject.org/about-cipa/#About